Advertisement

Odds of moderate or severe gastric ulceration in racehorses receiving antiulcer medications

James A. OrsiniNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by James A. Orsini in
Current site
Google Scholar
PubMed
Close
 DVM
,
Marie HaddockNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by Marie Haddock in
Current site
Google Scholar
PubMed
Close
 BS
,
Lynne StineNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by Lynne Stine in
Current site
Google Scholar
PubMed
Close
 BA
,
Eileen K. SullivanNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by Eileen K. Sullivan in
Current site
Google Scholar
PubMed
Close
 DVM
,
Tara S. RabuffoNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by Tara S. Rabuffo in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Gary SmithNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348.

Search for other papers by Gary Smith in
Current site
Google Scholar
PubMed
Close
 DPhil

Abstract

Objective—To determine the odds of moderate or severe gastric ulceration in racehorses treated with various antiulcer medications.

Design—Unmatched case-control study.

Animals—798 horses in active race training (252 Thoroughbreds and 546 Standardbreds). Only horses that had been receiving a single antiulcer medication or no antiulcer medication for at least 2 weeks prior to examination were included.

Procedure—Gastroscopy was performed on each horse by a single individual who was not aware of the horses' antiulcer treatments, and severity of gastric ulceration was scored. Signalment and medication history were recorded. Logistic regression was used to determine whether identification of moderate or severe ulceration was associated with treatment, age, breed, or sex. Treatments were grouped as no treatment, buffer, sucralfate, histamine type 2 receptor antagonist, compounded omeprazole, proprietary omeprazole at a low dosage, and proprietary omeprazole at a high dosage.

Results—Only proprietary omeprazole was associated with significantly lower odds of moderate or severe ulceration, compared with no treatment. Risks of moderate or severe gastric ulceration in horses receiving a buffer, sucralfate, a histamine type 2 receptor antagonist, or compounded omeprazole were not significantly different from risks in horses receiving no antiulcer medication.

Conclusions and Clinical Relevance—Results suggest that the proprietary formulation of omeprazole was associated with a significantly lower risk of moderate or severe gastric ulceration, compared with no treatment, in racehorses in active race training, whereas other antiulcer medications were not. (J Am Vet Med Assoc 2003;223:336–339)

Abstract

Objective—To determine the odds of moderate or severe gastric ulceration in racehorses treated with various antiulcer medications.

Design—Unmatched case-control study.

Animals—798 horses in active race training (252 Thoroughbreds and 546 Standardbreds). Only horses that had been receiving a single antiulcer medication or no antiulcer medication for at least 2 weeks prior to examination were included.

Procedure—Gastroscopy was performed on each horse by a single individual who was not aware of the horses' antiulcer treatments, and severity of gastric ulceration was scored. Signalment and medication history were recorded. Logistic regression was used to determine whether identification of moderate or severe ulceration was associated with treatment, age, breed, or sex. Treatments were grouped as no treatment, buffer, sucralfate, histamine type 2 receptor antagonist, compounded omeprazole, proprietary omeprazole at a low dosage, and proprietary omeprazole at a high dosage.

Results—Only proprietary omeprazole was associated with significantly lower odds of moderate or severe ulceration, compared with no treatment. Risks of moderate or severe gastric ulceration in horses receiving a buffer, sucralfate, a histamine type 2 receptor antagonist, or compounded omeprazole were not significantly different from risks in horses receiving no antiulcer medication.

Conclusions and Clinical Relevance—Results suggest that the proprietary formulation of omeprazole was associated with a significantly lower risk of moderate or severe gastric ulceration, compared with no treatment, in racehorses in active race training, whereas other antiulcer medications were not. (J Am Vet Med Assoc 2003;223:336–339)